

DETAILED CONTENTS

<u>CHAPTER</u>		<u>PAGE</u>
1	BACKGROUND AND RATIONALE	1-1
1.1	Allogeneic Umbilical Cord Blood Banking and Transplantation	1-1
1.1.1	Overview	1-1
1.1.2	Unrelated Donor UCB Transplantation	1-1
1.1.2.1	The New York Blood Center Placental Blood Program	1-2
1.1.2.2	Combined Clinical Results from Duke University and University of Minnesota	1-3
1.1.2.3	Unrelated UCB Transplantation in Adult Recipients- Duke University	1-5
1.2	COBLT Study Background	1-7
1.3	Transplant Study Overview	1-8
1.4	Cord Blood Bank Study Overview	1-9
1.5	References	1-10
2	STUDY DESIGN	2-1
2.1	Study Endpoints and Definitions	2-1
2.1.1	Primary and Secondary Graft Failure	2-1
2.1.2	Neutrophil Engraftment	2-2
2.1.3	Platelet Engraftment	2-2
2.1.4	RBC Engraftment	2-2
2.1.5	Acute and Chronic GVHD	2-2
2.1.6	Veno-Occlusive Disease	2-3
2.1.7	Interstitial Pneumonitis	2-3
2.1.8	Infection Grading	2-3
2.1.9	Relapse and Residual Disease	2-3
2.1.10	Disease-Free Survival	2-5
2.2	Eligibility and Exclusion Criteria	2-5
2.2.1	Eligibility Criteria	2-5
2.2.2	Exclusion Criteria	2-10

<u>CHAPTER</u>		<u>PAGE</u>
2	STUDY DESIGN (continued)	
2.3	Registration Procedures	2-10
2.3.1	Registration Procedures	2-10
2.3.2	Stratification Variables	2-11
2.4	Treatment Plan	2-11
2.4.1	Conditioning Regimen for Patients with Malignant Diseases or Severe Aplastic Anemia	2-11
2.4.2	Conditioning Regimen for Patients with Fanconi Anemia	2-14
2.4.3	Conditioning Regimen for Patients with Inborn Errors of Metabolism/Storage Disease	2-15
2.4.4	Conditioning Regimen for Patients with Other Non-Malignant Diseases	2-16
2.4.5	Non-TBI-Containing Conditioning Regimen for Patients with Malignant Diseases	2-17
2.4.6	Dose Adjustments	2-19
2.4.6.1	Cyclophosphamide Ideal Body Weight Dose Adjustment	2-19
2.4.6.2	Busulfan Dose Adjustment	2-20
2.4.7	GVHD Prophylaxis	2-20
2.4.7.1	Cyclosporine Prophylaxis	2-20
2.4.7.2	Corticosteroids	2-21
2.4.8	Cord Blood Infusion	2-21
2.4.9	Diagnosis of Acute GVHD	2-22
2.4.10	Diagnosis of Chronic GVHD	2-22
2.4.11	Use of Growth Factor	2-22
2.4.12	Prophylaxis Against Infections	2-23
2.4.12.1	Identification of Opportunistic Infections	2-23
2.4.12.2	Post-Transplant Immunization Schedule	2-24
2.4.13	Blood Product Support	2-24
2.4.14	CNS Prophylaxis	2-24
2.4.15	Miscellaneous Support Measures	2-24
2.5	Study Monitoring and Participant Risks	2-24
2.5.1	Follow-up Schedule	2-24
2.5.2	Required Observations	2-27
2.5.3	Weekly GVHD Monitoring	2-30
2.5.4	Risks and Toxicities	2-30
2.5.4.1	Reporting	2-32

<u>CHAPTER</u>	<u>PAGE</u>	
2	STUDY DESIGN (continued)	
2.6	Statistical Considerations	2-32
2.6.1	Sample Size and Power Considerations	2-32
2.6.2	Accrual Objectives	2-36
2.6.3	Early Stopping Guidelines	2-36
2.6.4	Primary Analyses	2-38
2.6.5	Secondary Analysis	2-38
2.6.6	References	2-39
2.7	Off-Study Cord Blood Transplants	2-39
3	LABORATORY PROCEDURES	3-1
3.1	HLA Typing	3-1
3.2	Characterization of Graft	3-2
3.3	Immune Reconstitution	3-4
3.3.1	Introduction and Objectives	3-4
3.3.2	Specific Aims	3-4
3.3.3	Schedule and Samples	3-5
3.4	Chimerism	3-7
	<u>APPENDICES</u>	App-1
A	Sample Consent Forms	App-2
A.1	Sample Consent Form for Patients with Malignant Diseases	App-3
A.2	Sample Consent Form for Patients with Non-Malignant Diseases	App-12
B	Staging and Grading of Acute GVHD	App-25
C	Chronic GVHD: Clinical and Pathological Manifestations	App-27
D	Toxicity Grading Scale	App-30
E	Derivation of a Sequential Test Statistic for Censored Exponential Data	App-33